More Industry News

  • Bayer Schering unveils expansion plan in Asia-Pacific

    Bayer Schering Pharma will make a major investment in its operations in Asia-Pacific "to become stronger in the market and to have the support to be able to grow above the market," said Alok Kanti, head of Bayer Schering's Asian-Pacific unit. The firm plans to boost its workforce in Vietnam and South Korea and double the size of its sales staff in India.

    Read more

  • Nigerian startup works to combat counterfeit drugs

    Sproxil, a startup in Nigeria, is gradually gaining support from investors and government entities to advance products intended to prevent the spread of counterfeit medicines. Aside from creating a text-messaging technology that enables customers to check the authenticity of drugs they purchase, Sproxil also teamed up with distributor Biofem Pharmaceuticals to test a scratch-label packaging for diabetes drug Glucophage to distinguish a genuine product from a fake one.

    Read more

  • Study: Avastin fails to boost combo's efficacy in prostate cancer

    Avastin did not help extend the survival of patients with advanced prostate cancer who received the drug in combination with docetaxel chemotherapy and prednisone, according to a study. Maker Roche Holding plans to continue testing Avastin for other tumor types.

    Read more

  • California agency allots $50M for early-stage stem cell studies

    The California Institute for Regenerative Medicine has allocated $50 million in funding for early-stage clinical trials of treatments based on embryonic or induced pluripotent stem cells. The institute will accept applications for grants or loans through July.

    Read more

  • HGS and BioInvent form partnership to research antibodies

    Human Genome Sciences will collaborate with BioInvent International to develop and market monoclonal antibodies for inflammation using BioInvent's discovery technology. The companies will share research, development and marketing costs as well as future revenue.

    Read more

  • Study notes increase in regulatory workload at biotech, drug firms

    A study suggests that research and commercialization outsourcing caused a dramatic increase in regulatory-affairs workload at biotech and pharmaceutical companies. "As more of the clinical function continues to be outsourced, regulatory affairs personnel will need to coordinate closely and communicate with external service providers. They will be challenged to handle a growing workload as their companies seek to improve R&D efficiency in an operating environment marked by ever-rising costs," a study author said.

    Read more

Powered by SmartBrief